Welcome to World Class Retina Care

Our practice was established in 1980 in central Phoenix. Since then, we have grown to include more than 35 locations throughout Arizona, providing improved access to the highest quality medical care. We are proud to have become Arizona’s largest and most experienced ophthalmology practice focused specifically on the diagnosis and management of the retina and vitreous.

At RCA, we believe in providing you with professional, attentive, and personal care while utilizing the latest technology and treatments. We accept new patients every day, and urgent or emergency referrals are seen the same day.

Find Your Location Today

May is Healthy Vision Awareness Month – take charge of your eye health!

Making healthy choices and getting regular eye exams can help reduce a person’s risk of vision loss. In support of Healthy Vision Month in May, we encourage everyone to take charge of their eye health and preserve their sight by following some simple tips.

Click here for more!

Latest News From RCA

May is Healthy Vision Awareness Month!

According to the American Academy of Ophthalmology, approximately 37 million adults in America have age-related macular degeneration, cataract, diabetic retinopathy, or glaucoma, all of which can cause visual impairment or blindness. However, recent studies show that making healthy choices and getting regular eye exams can help reduce a person’s risk of vision loss. In support… Read More »

Dr. Pravin U. Dugel: Predictive Data From the HAWK and HARRIER Studies (Video)

Pravin U. Dugel, MD, discusses the HAWK and HARRIER studies, particularly with regard to whether the disease activity assessment done at week 16 can predict which patients can be extended to 12 weeks. He also explains why this is important from a clinical standpoint. Interview from the 2018 ARVO Annual Meeting where leading experts recap… Read More »

Dr. Pravin U. Dugel, MD – VIDEO: Brolucizumab treatment frequency predicted by first dosing interval

HONOLULU — The recent HAWK and HARRIER trials of Novartis’ brolucizumab for the treatment of neovascular age-related macular degeneration has helped researchers predict which patients will need an 8-week dosing regimen or a 12-week regimen with an almost 90% predictability rate, Pravin Dugel, MD, said at the Association for Research in Vision and Ophthalmology meeting… Read More »